GlassScriptPhysician profile
Joannis Garcia
NPI 1114475183
$894.60
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $302.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $234.43 | 2021-2022 | |
| Abbvie INC. | $91.61 | 2021-2022 | |
| Lilly USA, LLC | $85.41 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.16 | 2021 | |
| Glaxosmithkline, LLC. | $77.91 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $64.41 | 2021-2022 | |
| Astellas Pharma US INC | $33.72 | 2021 | |
| Dexcom, INC. | $31.35 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.27 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $23.11 | 2021 | |
| Abbott Laboratories | $22.48 | 2022 | |
| Sun Pharmaceutical Industries INC. | $22.23 | 2022 | |
| Daiichi Sankyo INC. | $20.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.73 | 2021 | |
| Organon LLC | $17.51 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15.52 | 2022 | |
| Eisai INC. | $13.91 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.84 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joannis Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.